EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer – Current State and Evolving Standards

Swayamjeet Satapathy, Kunal R Chandekar, Nishikant A Damle

PET Clinics · 2026-07 · 21 (3) · 383-392

DOI: 10.1016/j.cpet.2026.02.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PET Clinics, 2026-07. Verfasst von Swayamjeet Satapathy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre & Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, Ind…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiopharmaceuticals, Antigens, Surface, Positron Emission Tomography Computed Tomography. Die Arbeit nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA)-based theranostics represent a paradigm shift in the management of prostate cancer. PSMA-ligand PET/computed tomography has demonstrated superior diagnostic accuracy over conventional imaging across diverse clinical settings. Parallelly, robust phase 3 evidence has established [177Lu]Lu-PSMA-617 radioligand therapy as a standard-of-care in metastatic castration-resistant prostate cancer (mCRPC), with significant improvements in survival end points and quality of life. Emerging data also support the safe and effective integration of [177Lu]Lu-PSMA-617 into earlier disease settings, including chemotherapy-naïve mCRPC and metastatic hormone-sensitive prostate cancer. Collectively, PSMA theranostics exemplify the crucial role of nuclear medicine in advancing precision care for prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiopharmaceuticalsAntigens, SurfacePositron Emission Tomography Computed TomographyGlutamate Carboxypeptidase IITheranostic NanomedicineHumansMaleLutetiumRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

Lutetium-177PET/CTPSMA radioligand therapyProstate cancerProstate-specific membrane antigen (PSMA)Theranostics

Substanzen

RadiopharmaceuticalsAntigens, SurfaceGlutamate Carboxypeptidase IIFOLH1 protein, humanLutetiumRadioisotopesProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre & Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, India.
  • Department of Nuclear Medicine, Manipal Hospitals, New Delhi, India.
  • Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India. Electronic address: nkantdamle@gmail.com.

Zitieren

APA

Satapathy, S., Chandekar, K. R., & Damle, N. A. (2026). Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer – Current State and Evolving Standards. PET Clinics, 21(3), 383-392. https://doi.org/10.1016/j.cpet.2026.02.002

Vancouver

Satapathy S, Chandekar KR, Damle NA. Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer – Current State and Evolving Standards. PET Clinics. 2026;21(3):383-392. doi:10.1016/j.cpet.2026.02.002

BibTeX
@article{Satapathy2026,
  author = {Satapathy, Swayamjeet and Chandekar, Kunal R and Damle, Nishikant A},
  title = {Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer – Current State and Evolving Standards},
  journal = {PET Clinics},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {383--392},
  doi = {10.1016/j.cpet.2026.02.002}
}
Kostenlos starten →